|
EP3674322A1
(en)
*
|
2002-02-25 |
2020-07-01 |
Biogen MA Inc. |
Administration of agents for the treatment of inflammation
|
|
US9415102B2
(en)
*
|
2002-09-06 |
2016-08-16 |
Alexion Pharmaceuticals, Inc. |
High concentration formulations of anti-C5 antibodies
|
|
US20050271660A1
(en)
*
|
2002-09-06 |
2005-12-08 |
Alexion Pharmaceuticals, Inc. |
Nebulization of monoclonal antibodies for treating pulmonary diseases
|
|
AU2003270330B2
(en)
*
|
2002-09-06 |
2009-07-30 |
Alexion Pharmaceuticals, Inc. |
Method of treatment of asthma using antibodies to complement component C5
|
|
WO2004071439A2
(en)
*
|
2003-02-10 |
2004-08-26 |
Elan Pharmaceuticals, Inc. |
Immunoglobulin formulation and method of preparation thereof
|
|
US20060104968A1
(en)
|
2003-03-05 |
2006-05-18 |
Halozyme, Inc. |
Soluble glycosaminoglycanases and methods of preparing and using soluble glycosaminogly ycanases
|
|
US8277810B2
(en)
|
2003-11-04 |
2012-10-02 |
Novartis Vaccines & Diagnostics, Inc. |
Antagonist anti-CD40 antibodies
|
|
LT1729810T
(lt)
*
|
2004-04-02 |
2018-11-26 |
Swedish Orphan Biovitrum Ab (Publ) |
Il-1ra agregacijos sumažinimo būdas
|
|
CA2478458A1
(en)
*
|
2004-08-20 |
2006-02-20 |
Michael Panzara |
Treatment of pediatric multiple sclerosis
|
|
JO3000B1
(ar)
|
2004-10-20 |
2016-09-05 |
Genentech Inc |
مركبات أجسام مضادة .
|
|
JP2008520717A
(ja)
*
|
2004-11-19 |
2008-06-19 |
バイオジェン・アイデック・エムエイ・インコーポレイテッド |
多発性硬化症についての処置
|
|
NZ560844A
(en)
*
|
2005-03-08 |
2008-08-29 |
Pharmacia & Upjohn Co Llc |
Anti-MAdCAM antibody compositions
|
|
CA2607663C
(en)
|
2005-05-19 |
2014-08-12 |
Amgen Inc. |
Compositions and methods for increasing the stability of antibodies
|
|
BRPI0615745A2
(pt)
*
|
2005-09-12 |
2011-05-24 |
Novimmune Sa |
formulação de anticorpo anti-cd3
|
|
US9309316B2
(en)
|
2005-12-20 |
2016-04-12 |
Bristol-Myers Squibb Company |
Stable subcutaneous protein formulations and uses thereof
|
|
JP5193881B2
(ja)
|
2005-12-29 |
2013-05-08 |
セントカー・インコーポレーテツド |
ヒト抗ｉｌ−２３抗体、組成物、方法および用途
|
|
CA3022097C
(en)
|
2006-03-15 |
2020-10-27 |
Alexion Pharmaceuticals, Inc. |
Treatment of paroxysmal nocturnal hemoglobinuria patients by an inhibitor of complement
|
|
TW200806315A
(en)
|
2006-04-26 |
2008-02-01 |
Wyeth Corp |
Novel formulations which stabilize and inhibit precipitation of immunogenic compositions
|
|
WO2008039761A2
(en)
*
|
2006-09-25 |
2008-04-03 |
Medimmune, Llc. |
Stabilized antibody formulations and uses thereof
|
|
ES2827180T3
(es)
*
|
2006-10-06 |
2021-05-20 |
Amgen Inc |
Formulaciones de anticuerpos estables
|
|
US7705132B2
(en)
*
|
2006-10-20 |
2010-04-27 |
Amgen Inc. |
Stable polypeptide formulations
|
|
JP5419709B2
(ja)
*
|
2007-01-09 |
2014-02-19 |
ワイス・エルエルシー |
抗ｉｌ−１３抗体製剤およびその使用
|
|
CA2677831A1
(fr)
*
|
2007-02-12 |
2008-08-21 |
Lassaad Boujbel |
Le sucralose solution sterile sans conservateurs
|
|
US20090208492A1
(en)
*
|
2007-06-14 |
2009-08-20 |
Elan Pharmaceuticals, Inc. |
Lyophilized Immunoglobulin Formulations and Methods of Preparation
|
|
TR201820837T4
(tr)
*
|
2007-06-14 |
2019-01-21 |
Biogen Ma Inc |
Natalizumab antikor formülasyonları.
|
|
WO2009003010A2
(en)
*
|
2007-06-25 |
2008-12-31 |
Becton, Dickinson And Company |
Methods for evaluating the aggregation of a protein in a suspension including organopolysiloxane and medical articles coated with organopolysiloxane containing a protein solution
|
|
EP2237038B1
(en)
*
|
2007-10-22 |
2015-04-29 |
Becton Dickinson and Company |
Medical articles coated with organopolysiloxane containing a protein solution and non-ionic surfactant
|
|
US8883146B2
(en)
|
2007-11-30 |
2014-11-11 |
Abbvie Inc. |
Protein formulations and methods of making same
|
|
TWI489994B
(zh)
|
2008-03-17 |
2015-07-01 |
Baxter Healthcare Sa |
供免疫球蛋白及玻尿酸酶之皮下投藥之用的組合及方法
|
|
WO2009124294A2
(en)
*
|
2008-04-05 |
2009-10-08 |
Lpath, Inc. |
Pharmaceutical compositions for binding sphingosine-1-phosphate
|
|
ES2406029T3
(es)
|
2008-04-15 |
2013-06-05 |
Grifols Therapeutics Inc. |
Ultrafiltración/diafiltración en dos fases
|
|
WO2010027766A1
(en)
|
2008-08-27 |
2010-03-11 |
Schering Corporation |
Lyophilized formulatons of engineered anti-il-23p19 antibodies
|
|
TWI516501B
(zh)
*
|
2008-09-12 |
2016-01-11 |
禮納特神經系統科學公司 |
Ｐｃｓｋ９拮抗劑類
|
|
JP2012510468A
(ja)
*
|
2008-11-28 |
2012-05-10 |
アボット・ラボラトリーズ |
安定な抗体組成物およびこれを安定させるための方法
|
|
AU2009334090B2
(en)
*
|
2008-12-29 |
2012-08-30 |
Samyang Biopharmaceuticals Corporation |
Pharmaceutical composition of lyophilized formulation and preparation method of the same
|
|
FR2940617B1
(fr)
*
|
2008-12-30 |
2012-04-20 |
Fractionnement Et Des Biotechonologies Lab Franc |
Composition d'immunoglobulines g
|
|
EP2419137A4
(en)
*
|
2009-04-17 |
2013-01-09 |
Biogen Idec Inc |
COMPOSITIONS AND METHOD FOR TREATING ACUTE MYELOGENIC LEUKEMIA
|
|
WO2010129469A1
(en)
*
|
2009-05-04 |
2010-11-11 |
Abbott Biotechnology Ltd. |
Stable high protein concentration formulations of human anti-tnf-alpha-antibodies
|
|
CN102655853B
(zh)
*
|
2009-09-17 |
2015-07-29 |
巴克斯特卫生保健有限公司 |
透明质酸酶和免疫球蛋白的稳定的复合制剂及其使用方法
|
|
HRP20190690T1
(hr)
*
|
2009-10-09 |
2019-06-28 |
Armagen, Inc. |
Postupci i pripravci za povećanje aktiviteta iduronat-2-sulfataze u centralnom nervnom sustavu
|
|
WO2011075185A1
(en)
|
2009-12-18 |
2011-06-23 |
Oligasis |
Targeted drug phosphorylcholine polymer conjugates
|
|
EP3216462A3
(en)
*
|
2010-02-26 |
2017-12-20 |
Novo Nordisk A/S |
Stable antibody containing compositions
|
|
EA201291065A1
(ru)
|
2010-04-16 |
2013-03-29 |
Байоджен Айдек Ма Инк. |
Антитела против vla-4
|
|
KR20130086144A
(ko)
|
2010-05-28 |
2013-07-31 |
노보 노르디스크 에이/에스 |
항체 및 보존제를 포함하는 안정한 다중-투여 조성물
|
|
AU2011262346B2
(en)
|
2010-06-04 |
2014-12-11 |
Wyeth Llc |
Streptococcus pneumoniae vaccine formulations
|
|
EP3578205A1
(en)
|
2010-08-06 |
2019-12-11 |
ModernaTX, Inc. |
A pharmaceutical formulation comprising engineered nucleic acids and medical use thereof
|
|
EA027353B1
(ru)
|
2010-09-17 |
2017-07-31 |
Баксалта Инкорпорейтид |
СТАБИЛИЗАЦИЯ ИММУНОГЛОБУЛИНОВ С ПОМОЩЬЮ ВОДНОГО СОСТАВА С ГИСТИДИНОМ ПРИ pH ОТ СЛАБОКИСЛОГО ДО НЕЙТРАЛЬНОГО
|
|
CN103429606A
(zh)
|
2010-10-01 |
2013-12-04 |
现代治疗公司 |
设计核酸及其使用方法
|
|
ES2654820T3
(es)
|
2010-10-25 |
2018-02-15 |
Biogen Ma Inc. |
Métodos para determinar diferencias en la actividad de la alfa-4-integrina mediante la correlación de las diferencias en los niveles de sVCAM y/o sMAdCAM
|
|
HRP20161753T1
(hr)
|
2010-11-11 |
2017-02-10 |
Abbvie Biotechnology Ltd |
Tekuće formulacije protutijela anti-tnf-alfa s visokom koncentracijom
|
|
AR083847A1
(es)
|
2010-11-15 |
2013-03-27 |
Novartis Ag |
Variantes de fc (fragmento constante) silenciosas de los anticuerpos anti-cd40
|
|
RU2563346C2
(ru)
|
2011-03-31 |
2015-09-20 |
Мерк Шарп И Доум Корп. |
Стабильные составы антител против рецептора программируемой смерти pd-1 человека и относящиеся к ним способы лечения
|
|
CA2831613A1
(en)
|
2011-03-31 |
2012-10-04 |
Moderna Therapeutics, Inc. |
Delivery and formulation of engineered nucleic acids
|
|
BR112013030236A2
(pt)
*
|
2011-05-26 |
2016-12-06 |
Glaxosmithkline Biolog Sa |
preparação em massa de vírus da dengue inativado ou uma composição imunogênica, e, preparação liofilizada de vírus da dengue inativado
|
|
US10995130B2
(en)
*
|
2011-07-01 |
2021-05-04 |
Biogen Ma Inc. |
Arginine-free TNFR:Fc-fusion polypeptide compositions and methods of use
|
|
US9464124B2
(en)
|
2011-09-12 |
2016-10-11 |
Moderna Therapeutics, Inc. |
Engineered nucleic acids and methods of use thereof
|
|
KR20190099538A
(ko)
|
2011-10-03 |
2019-08-27 |
모더나 세라퓨틱스, 인코포레이티드 |
변형된 뉴클레오사이드, 뉴클레오타이드, 및 핵산, 및 이들의 용도
|
|
EP4144378A1
(en)
|
2011-12-16 |
2023-03-08 |
ModernaTX, Inc. |
Modified nucleoside, nucleotide, and nucleic acid compositions
|
|
AU2013212587B2
(en)
*
|
2012-01-23 |
2017-07-20 |
Regeneron Pharmaceuticals, Inc. |
Stabilized formulations containing anti-Ang2 antibodies
|
|
JP6265970B2
(ja)
*
|
2012-03-26 |
2018-01-24 |
サノフイ |
安定なＩｇＧ４に基づく結合剤の製剤
|
|
US9592289B2
(en)
|
2012-03-26 |
2017-03-14 |
Sanofi |
Stable IgG4 based binding agent formulations
|
|
US9254311B2
(en)
|
2012-04-02 |
2016-02-09 |
Moderna Therapeutics, Inc. |
Modified polynucleotides for the production of proteins
|
|
US9572897B2
(en)
|
2012-04-02 |
2017-02-21 |
Modernatx, Inc. |
Modified polynucleotides for the production of cytoplasmic and cytoskeletal proteins
|
|
AU2013243954A1
(en)
|
2012-04-02 |
2014-10-30 |
Moderna Therapeutics, Inc. |
Modified polynucleotides for the production of cosmetic proteins and peptides
|
|
US9283287B2
(en)
|
2012-04-02 |
2016-03-15 |
Moderna Therapeutics, Inc. |
Modified polynucleotides for the production of nuclear proteins
|
|
US20140004131A1
(en)
|
2012-05-04 |
2014-01-02 |
Novartis Ag |
Antibody formulation
|
|
AR091902A1
(es)
|
2012-07-25 |
2015-03-11 |
Hanmi Pharm Ind Co Ltd |
Formulacion liquida de un conjugado de insulina de accion prolongada
|
|
US8883979B2
(en)
|
2012-08-31 |
2014-11-11 |
Bayer Healthcare Llc |
Anti-prolactin receptor antibody formulations
|
|
EP2727602A1
(en)
*
|
2012-10-31 |
2014-05-07 |
Takeda GmbH |
Method for preparation of a high concentration liquid formulation of an antibody
|
|
DK2922554T3
(en)
|
2012-11-26 |
2022-05-23 |
Modernatx Inc |
Terminalt modificeret rna
|
|
UA117466C2
(uk)
|
2012-12-13 |
2018-08-10 |
Мерк Шарп Енд Доме Корп. |
СТАБІЛЬНИЙ СКЛАД У ВИГЛЯДІ РОЗЧИНУ АНТИТІЛА ДО IL-23p19
|
|
US8980864B2
(en)
|
2013-03-15 |
2015-03-17 |
Moderna Therapeutics, Inc. |
Compositions and methods of altering cholesterol levels
|
|
PL3041513T3
(pl)
|
2013-09-08 |
2021-01-25 |
Kodiak Sciences Inc. |
Obojnaczojonowe polimerowe koniugaty czynnika viii
|
|
US10023626B2
(en)
|
2013-09-30 |
2018-07-17 |
Modernatx, Inc. |
Polynucleotides encoding immune modulating polypeptides
|
|
BR112016007255A2
(pt)
|
2013-10-03 |
2017-09-12 |
Moderna Therapeutics Inc |
polinucleotídeos que codificam receptor de lipoproteína de baixa densidade
|
|
ES2983564T3
(es)
|
2013-11-21 |
2024-10-23 |
Genmab As |
Formulación liofilizada de conjugado de anticuerpos y fármaco
|
|
US9932591B2
(en)
|
2013-12-18 |
2018-04-03 |
University Of Delaware |
Reduction of lipase activity in product formulations
|
|
US9840553B2
(en)
|
2014-06-28 |
2017-12-12 |
Kodiak Sciences Inc. |
Dual PDGF/VEGF antagonists
|
|
KR102210104B1
(ko)
|
2014-10-17 |
2021-02-01 |
코디악 사이언시스 인코포레이티드 |
부티릴콜린에스테라제 양성이온성 중합체 컨쥬게이트
|
|
AR104847A1
(es)
|
2015-06-17 |
2017-08-16 |
Lilly Co Eli |
Formulación de anticuerpo anti-cgrp
|
|
WO2017015198A1
(en)
*
|
2015-07-17 |
2017-01-26 |
Coherus Biosciences, Inc. |
Stable aqeous formulations of natalizumab
|
|
US10484453B2
(en)
*
|
2015-07-29 |
2019-11-19 |
Xerox Corporation |
System and method for printing documents using print hardware and automatic context inference
|
|
CA3010056A1
(en)
|
2015-12-30 |
2017-07-06 |
Kodiak Sciences Inc. |
Antibodies and conjugates thereof
|
|
WO2017121867A1
(en)
|
2016-01-13 |
2017-07-20 |
Genmab A/S |
Formulation for antibody and drug conjugate thereof
|
|
US10914720B2
(en)
|
2016-02-10 |
2021-02-09 |
Becton Dickinson France |
Method to evaluate the stability of a protein-based formulation
|
|
EP3541413A2
(en)
|
2016-11-21 |
2019-09-25 |
Polpharma Biologics S.A. |
Aqueous pharmaceutical formulations
|
|
JOP20190260A1
(ar)
|
2017-05-02 |
2019-10-31 |
Merck Sharp & Dohme |
صيغ ثابتة لأجسام مضادة لمستقبل الموت المبرمج 1 (pd-1) وطرق استخدامها
|
|
CA3060581A1
(en)
|
2017-05-02 |
2018-11-08 |
Merck Sharp & Dohme Corp. |
Formulations of anti-lag3 antibodies and co-formulations of anti-lag3 antibodies and anti-pd-1 antibodies
|
|
ES2938608T3
(es)
*
|
2017-09-20 |
2023-04-13 |
Tillotts Pharma Ag |
Método para preparar una forma farmacéutica sólida que comprende anticuerpos mediante granulación en húmedo, extrusión y esferonización
|
|
KR102686858B1
(ko)
|
2017-12-06 |
2024-07-19 |
머크 샤프 앤드 돔 엘엘씨 |
스트렙토코쿠스 뉴모니아에 폴리사카라이드-단백질 접합체를 포함하는 조성물 및 그의 사용 방법
|
|
CA3081144A1
(en)
*
|
2017-12-08 |
2019-06-13 |
Argenx Bvba |
Use of fcrn antagonists for treatment of generalized myasthenia gravis
|
|
US20210031012A1
(en)
|
2018-01-26 |
2021-02-04 |
Progenity, Inc. |
Treatment of a disease of the gastrointestinal tract with a pde4 inhibitor
|
|
CN112203679A
(zh)
|
2018-03-02 |
2021-01-08 |
科达制药股份有限公司 |
Il-6抗体及其融合构建体和缀合物
|
|
US20190269757A1
(en)
|
2018-03-05 |
2019-09-05 |
Janssen Biotech, Inc. |
Methods of Treating Crohn's Disease with Anti-IL23 Specific Antibody
|
|
US11426446B2
(en)
|
2018-03-08 |
2022-08-30 |
Coherus Biosciences, Inc. |
Stable aqueous formulations of aflibercept
|
|
US11667702B2
(en)
|
2018-03-08 |
2023-06-06 |
Coherus Biosciences, Inc. |
Stable aqueous formulations of aflibercept
|
|
TWI841554B
(zh)
|
2018-03-21 |
2024-05-11 |
丹麥商珍美寶股份有限公司 |
以鉑為主之劑與抗組織因子抗體－藥物共軛物的組合治療癌症之方法
|
|
AU2019251453A1
(en)
|
2018-04-10 |
2020-11-26 |
Dr. Reddy’S Laboratories Limited |
Stable formulations of therapeutic antibody
|
|
SG11202009874QA
(en)
*
|
2018-04-10 |
2020-11-27 |
Dr Reddys Laboratories Ltd |
Antibody formulation
|
|
JP2021521168A
(ja)
*
|
2018-04-10 |
2021-08-26 |
ドクター レディズ ラボラトリーズ リミテッド |
安定な抗体製剤
|
|
CA3099547A1
(en)
|
2018-05-07 |
2019-11-14 |
Reshma Abdulla RANGWALA |
Methods of treating cancer with a combination of an anti-pd-1 antibody and an anti-tissue factor antibody-drug conjugate
|
|
US12037398B2
(en)
|
2018-06-04 |
2024-07-16 |
Biogen Ma Inc. |
Anti-VLA-4 antibodies having reduced effector function
|
|
MX2020013195A
(es)
|
2018-06-08 |
2021-02-26 |
Argenx Bvba |
Composiciones y metodos para el tratamiento de la trombocitopenia inmunitaria.
|
|
US12227565B2
(en)
|
2018-06-20 |
2025-02-18 |
Biora Therapeutics, Inc. |
Method of formulating a pharmaceutical composition comprising administering an immune modulator to the small intestine
|
|
US12171764B2
(en)
|
2018-06-20 |
2024-12-24 |
Biora Therapeutics, Inc. |
Treatment of a disease of the gastrointestinal tract with a JAK or other kinase inhibitor
|
|
EP3810268A1
(en)
|
2018-06-20 |
2021-04-28 |
Progenity, Inc. |
Treatment of a disease of the gastrointestinal tract with an il-12/il-23 inhibitor
|
|
EP3810095A1
(en)
|
2018-06-20 |
2021-04-28 |
Progenity, Inc. |
Treatment of a disease of the gastrointestinal tract with a tnf inhibitor
|
|
WO2019246455A1
(en)
|
2018-06-20 |
2019-12-26 |
Progenity, Inc. |
Treatment of a disease of the gastrointestinal tract with an integrin inhibitor
|
|
WO2019246312A1
(en)
|
2018-06-20 |
2019-12-26 |
Progenity, Inc. |
Treatment of a disease of the gastrointestinal tract with an immunomodulator
|
|
CN112566652A
(zh)
|
2018-06-25 |
2021-03-26 |
Jcr制药股份有限公司 |
含有蛋白的水性液体制剂
|
|
TWI844571B
(zh)
|
2018-10-30 |
2024-06-11 |
丹麥商珍美寶股份有限公司 |
使用抗血管內皮生長因子（ｖｅｇｆ）抗體與抗組織因子（ｔｆ）抗體－藥物共軛體之組合以治療癌症之方法
|
|
BR112021008873A8
(pt)
|
2018-11-07 |
2023-04-11 |
Merck Sharp & Dohme |
Formulação
|
|
BR112021009287A2
(pt)
|
2018-11-20 |
2021-10-26 |
Janssen Biotech, Inc. |
Método seguro e eficaz para tratar psoríase com anticorpo específico anti-il-23
|
|
WO2020131763A2
(en)
|
2018-12-19 |
2020-06-25 |
Merck Sharp & Dohme Corp. |
Compositions comprising streptococcus pneumoniae polysaccharide-protein conjugates and methods of use thereof
|
|
TWI827732B
(zh)
*
|
2018-12-24 |
2024-01-01 |
大陸商遠大賽威信生命科學（南京）有限公司 |
用於治療b型肝炎的藥物製劑及其製備方法和用途
|
|
CN113874073A
(zh)
|
2019-05-23 |
2021-12-31 |
詹森生物科技公司 |
用针对IL-23和TNFα的抗体的联合疗法治疗炎性肠病的方法
|
|
MX2021014756A
(es)
*
|
2019-06-07 |
2022-01-18 |
Argenx Bvba |
Formulaciones farmaceuticas de inhibidores de fcrn adecuadas para administracion subcutanea.
|
|
EP3983079A1
(en)
*
|
2019-06-11 |
2022-04-20 |
MacroGenics, Inc. |
Pharmaceutical formulations of bi-specific diabodies and use of the same
|
|
AU2020319897A1
(en)
*
|
2019-08-01 |
2022-02-24 |
Momenta Pharmaceuticals, Inc. |
FcRn antibodies and methods of use thereof
|
|
WO2021050687A1
(en)
|
2019-09-10 |
2021-03-18 |
Coherus Biosciences, Inc. |
Stable aqueous formulations of aflibercept
|
|
CN114786731A
(zh)
|
2019-10-10 |
2022-07-22 |
科达制药股份有限公司 |
治疗眼部病症的方法
|
|
US20230041642A1
(en)
*
|
2019-12-16 |
2023-02-09 |
Nipro Corporation |
Aggregation Inhibitory Agent and Medical Composition and Medical Device Including Same
|
|
TW202140552A
(zh)
|
2020-01-08 |
2021-11-01 |
比利時商阿根思公司 |
用於治療天皰瘡病症的方法
|
|
EP4090368A1
(en)
*
|
2020-01-13 |
2022-11-23 |
Aptevo Research and Development LLC |
Methods and compositions for preventing adsorption of therapeutic proteins to drug delivery system components
|
|
EP4096802A4
(en)
*
|
2020-01-29 |
2024-07-03 |
Merck Sharp & Dohme LLC |
METHOD FOR SEPARATION OF HOST CELL LIPASES FROM ANTI-LAG3 ANTIBODY PRODUCTION
|
|
CN115768466A
(zh)
|
2020-05-21 |
2023-03-07 |
詹森生物科技公司 |
用抗IL-23和TNFα抗体的联合疗法治疗炎性肠病的方法
|
|
US20230340131A1
(en)
*
|
2020-11-12 |
2023-10-26 |
Dr. Reddy’S Laboratories Limited |
Stable aqueous high concentration formulation of integrin antibody
|
|
WO2023174925A1
(en)
|
2022-03-14 |
2023-09-21 |
Novimmune Sa |
Bispecific gpc3xcd28 and gpc3xcd3 antibodies and their combination for targeted killing of gpc3 positive malignant cells
|
|
CA3258002A1
(en)
|
2022-06-15 |
2023-12-21 |
argenx BV |
FCRN BINDING MOLECULES AND METHODS OF USE
|
|
WO2024249568A1
(en)
|
2023-05-30 |
2024-12-05 |
Paragon Therapeutics, Inc. |
Alpha4beta7 integrin antibody compositions and methods of use
|